Lataa...
HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer’s disease in a three cohorts study
Several retrospective epidemiological studies report that utilization of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors called statins at mid-life can reduce the risk of developing sporadic Alzheimer’s disease (AD) by as much as 70%. Conversely, administration of these inhibitors in cli...
Tallennettuna:
| Julkaisussa: | Mol Psychiatry |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4318698/ https://ncbi.nlm.nih.gov/pubmed/25023145 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mp.2014.81 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|